Dev

Investigating the role of Myosin VI in quality control of mitochondria linked to Parkinson’s disease pathology Investments > €500k United Kingdom Parkinson’s disease & PD-related disorders 2016    

HQLC Dementia Carers Instrument Development: DECIDE Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016    

Dkk1-Wnt signalling pathway in synapse degeneration: implication for early stages of Alzheimer’s disease Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016    

Tackling autophagy and apoptosis for the potential therapy of Huntington’s Disease Investments > €500k United Kingdom Huntington’s disease 2016    

Deficient Wnt signalling in synapse degeneration and its contribution to Parkinson’s Disease Investments > €500k United Kingdom Parkinson’s disease & PD-related disorders 2016    

Pathway-driven identification of therapeutic targets for combatting Alzheimer’s disease. Investments > €500k United Kingdom Alzheimer’s disease & other dementias 2016    

Targeting Parkin and Mitochondrial Dynamics in Huntington’s disease Investments > €500k United Kingdom Huntington’s disease 2016    

Role of microtubule acetylation in Parkinson’s disease Investments > €500k United Kingdom Parkinson’s disease & PD-related disorders 2016    

Investigating mechanistic causes of C9ORF72-related amyotrophic lateral sclerosis (ALS). Investments > €500k United Kingdom Motor neurone diseases 2016    

The role of variant (v)U1 snRNAs in development and disease. Investments > €500k United Kingdom Neurodegenerative disease in general|Spinal muscular atrophy (SMA) 2016